PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1544588
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1544588
Retinal Disorder Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
Global Retinal Disorder Treatment Market is poised to attain a 9.6% CAGR from 2024 to 2032, driven by the increasing prevalence of retinal disorders and advancements in treatment technologies. Retinal disorders, such as macular degeneration and diabetic retinopathy, are becoming more common due to an aging population and rising rates of chronic conditions like diabetes. Additionally, the increasing funding and efforts in research and development support the market.
For instance, in July 2024, a new three-year, $1.5 million grant from the Foundation Fighting Blindness was granted for retinal disorder research. Shigemi Matsuyama, an associate professor of ophthalmology and visual sciences at Case Western Reserve University School of Medicine, was assigned to investigate a potentially groundbreaking oral drug.
The demand for effective and innovative treatment options is fueling market growth. Additionally, advancements in drug delivery systems and therapeutic innovations are enhancing the efficacy of retinal disorder treatments, supporting market expansion.
The overall Retinal Disorder Treatment Industry is classified based on the type, dosage form, distribution channel, and region.
Macular degeneration, particularly age-related macular degeneration (AMD), is anticipated to be a major growth driver within the Retinal Disorder Treatment Market. AMD is a leading cause of vision loss among the elderly, driving significant demand for effective treatments. The market for macular degeneration treatments includes both anti-VEGF therapies and emerging gene therapies. Anti-VEGF treatments are currently the most widely used and have demonstrated substantial effectiveness in slowing disease progression and improving visual acuity. The continuous development of novel therapies and improved treatment protocols will boost market growth in this segment.
The eye solutions segment, categorized by dosage forms such as intravitreal injections, eye drops, and implants, will showcase substantial growth. Intravitreal injections are gaining prominence due to their direct delivery of drugs into the vitreous body, ensuring higher bioavailability and efficacy for retinal disorders. Eye drops and implants also play a crucial role in the treatment landscape, offering patient-friendly options and sustained drug release. The evolution of drug delivery technologies and the introduction of innovative dosage forms are driving the adoption of eye solutions in the retinal disorder treatment market.
Europe will experience significant growth in the Retinal Disorder Treatment Market from 2024 to 2032. The region benefits from a robust healthcare infrastructure, high investment in medical research, and a rising prevalence of retinal disorders. European countries are at the forefront of adopting advanced treatment options, supported by favorable regulatory frameworks and government initiatives promoting healthcare innovation. The presence of leading pharmaceutical and biotechnology companies further strengthens the market, with ongoing research and development efforts driving the introduction of new and improved therapies for retinal disorders.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of diabetes
- 3.2.1.2 Rising geriatric population
- 3.2.1.3 Technological advancements
- 3.2.1.4 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High treatment cost
- 3.2.2.2 Side effects and safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
- 3.7 Future market trends
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Diabetic retinopathy
- 5.3 Macular degeneration
- 5.3.1 Dry macular degeneration
- 5.3.2 Wet macular degeneration
- 5.4 Diabetic macular edema
- 5.5 Retinal vein occlusion
- 5.6 Other types
Chapter 6 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Capsules and tablets
- 6.3 Eye drops
- 6.4 Eye solutions
- 6.5 Gels
- 6.6 Ointments
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacies
- 7.3 Retail pharmacies
- 7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AbbVie Inc.
- 9.2 Alimera Sciences, Inc.
- 9.3 Alcon, Inc.
- 9.4 Bayer AG
- 9.5 Biogen Inc.
- 9.6 Bausch Health Companies
- 9.7 F. Hoffmann-La Roche Ltd.
- 9.8 Graybug Vision, Inc.
- 9.9 Merck and Co., Inc.
- 9.10 Novartis AG
- 9.11 Ophthotech Corporation
- 9.12 Pfizer, Inc.
- 9.13 Regeneron Pharmaceuticals Inc.
- 9.14 Santen Pharmaceuticals Co. Ltd.
- 9.15 Takeda Pharmaceutical Company Limited
